Abstract 2736
Background
TMB is a clinically relevant biomarker associated with response to immune checkpoint inhibitors in patients with NSCLC. Tumor TMB (tTMB) can be assessed by next-generation sequencing (NGS) gene panels; however, obtaining sufficient tumor tissue can be challenging, and NGS methods have been developed for TMB assessment from blood (bTMB). We compared bTMB values using 3 commercial NGS assays that differ in gene number, depth of coverage, and variant allele cutoff.
Methods
bTMB was assessed in 25 commercial NSCLC plasma samples with 3 NGS assays, and values were compared by Spearman’s correlation. For assay A, < 500 genes were sequenced to a depth of < 1000x. Assays B and C each comprised > 500 genes, sequenced to a depth of ∼ 1500x. To determine concordance between bTMB and tTMB we assessed 86 commercial NSCLC matched plasma and tumor samples using bTMB assays A and C and a clinically validated tTMB gene panel assay, and performed subgroup analysis by disease stage.
Results
bTMB in stage I–III NSCLC samples assessed by assays B and C showed greater correlation (r = 0.78) than by assays A and B (r = 0.59) and A and C (r = 0.53). Across 86 matched samples, tTMB and bTMB concordance was lower for assay A (r = 0.24) than assay C (r = 0.51) and was higher among stage IV NSCLC samples (A, r = 0.38; C, r = 0.72) than stage I–III (A, r = 0.24; C, r = 0.40). Using clinically relevant cutoffs, high bTMB was observed in 5/30 patients with assay A (range: 10.5–21.1), and 19/30 patients with assay C (range: 12.4–67.6); high tTMB ranged from 10.0 to 36.6.
Conclusions
In patients with NSCLC, bTMB was concordant (r > 0.5) between 3 NGS assays. Concordance between bTMB and tTMB varied and was improved for bTMB assays with increased coverage and sequencing depth, and in patients with higher stage metastatic disease. Assay parameters impact accurate and reproducible TMB assessment, with lower coverage and sequencing depth, and differing variant allele cutoff, risking false-negative results that may affect outcomes in response to immune checkpoint inhibitor therapy. These data underscore the need for demonstrating clinical utility of bTMB assays and for assessment of bridging analytical performance between assays.
Clinical trial identification
Editorial acknowledgement
Amrita Dervan, PhD, and Jay Rathi, MA, of Spark Medica Inc, funded by BristolMyers Squibb.
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Disclosure
J. Baden: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb; Shareholder/Stockholder/Stock options: Johnson & Johnson. H. Chang: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. D.M. Greenawalt: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. S. Kirov: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. S. Pant: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. A. Seminara: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. S. Srinivasan: Shareholder / Stockholder / Stock options, Full/Part-time employment: Bristol-Myers Squibb. G. Green: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract